Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, adults with mild-to-moderate hair damage taking GPVGPS Collagen® daily for 24 weeks showed significant improvements in hair luster, strength, thickness, and density compared to placebo, with no safety concerns reported.

This study found that a hair tonic containing 10% mesenchymal stem cell secretome significantly increased hair density in volunteers with alopecia after eight weeks, suggesting its potential as an effective treatment option for hair growth stimulation.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

In this prospective study, individuals with androgenetic alopecia using a home-use low-level laser therapy helmet for 48 weeks experienced significant increases in hair density and thickness, with reported improvements consistent across sexes and no device-related adverse events.

In this study, a female dog with ectoparasite infestation was treated for two weeks using wormectin, diphenhydramine, chlorpheniramine maleate, dexamethasone, and amoxicillin, resulting in improved symptoms such as reduced itching, closure of skin ulcers, and hair regrowth.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This study found that platelet-rich plasma therapy led to greater improvements in hair density and patient satisfaction compared to topical 5% Minoxidil in androgenetic alopecia patients over 12 weeks.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

In this case report, acute liver failure was attributed to a 34-year-old woman's high-dose zinc supplementation taken for three weeks, illustrating that even commonly used supplements can lead to serious conditions like liver failure.

In this study, oral supplementation with NMN for 12 weeks in middle-aged Japanese women significantly increased hair growth density and diameter and improved subjective assessments of hair texture and quality of life, with no significant changes in hair hormone concentrations observed.

In this observational study, patients in India using Sebamed® anti-hair-loss shampoo for 16 weeks experienced improvements in hair growth, thickness, hair fall count, and density, with healthcare professionals reporting good to excellent tolerability in 96.4% of cases.

In this study, 5mg oral minoxidil given daily for 24 weeks significantly increased hair thickness and scalp appearance among 27 male patients with androgenetic alopecia, although some experienced side effects like hypertrichosis and mild headaches.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

This case study reports that a 45-year-old woman developed a painless nodule in the lower lip four weeks after receiving hyaluronic acid filler, which required surgical removal, highlighting the potential for delayed complications from lip augmentation procedures.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

This study found that a hair serum with plant-derived ingredients significantly reduced hair loss in women with chronic telogen effluvium over 16 weeks, and was well-tolerated, leading to improved hair characteristics and quality of life compared to a control group.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

This study found that combining platelet-rich plasma with topical minoxidil led to the greatest increase in terminal hair density at 32 weeks, while low-dose oral minoxidil was more effective at reducing vellus hair density in men with androgenetic alopecia.

In this randomized trial, lupus patients taking daily 200 μg selenium supplements for eight weeks showed significant improvements in metabolic markers like CRP, ESR, MDA, and GPX, as well as reduced clinical symptoms such as arthritis and alopecia, compared to those receiving a placebo.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This study found that among mother-infant pairs during the COVID-19 pandemic, lower maternal hair cortisol concentrations during pregnancy, combined with higher levels at six weeks postpartum, were associated with poorer infant developmental outcomes at six months.

This case report details the occurrence of alopecic scalp cysts in a young female following three weeks of isotretinoin treatment for acne, highlighting a potential side effect for clinicians to recognize.

This study observed that middle-aged women with Polycystic Ovary Syndrome who practiced yoga Nidra for twelve weeks experienced improvements in stress, anxiety, and depression compared to a control group that did not participate in any intervention.